What is PCOS?

What is PCOS?

Despite what the name suggests, Polycystic Ovary Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PCOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.

At its core, PCOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PCOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PCOS so challenging—and why understanding your unique experience matters.

So, how can the PCOS Association help?

We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PCOS—and make progress.

Here’s what you’ll find at PCOSA:

  • Reliable, science-backed information about what PCOS is (and isn’t)

  • 💬 Supportive communities of people who understand exactly what you’re going through

  • 🧬 Resources for navigating fertility, metabolic health, nutrition, and more

  • 🧠 Education for providers who want to better support their PCOS patients

  • 🙋‍♀️ Advocacy to make sure PCOS is recognized, researched, and respected

No fluff. No fad cures. Just real support, grounded in evidence and compassion.

At PCOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.

pcos

pcos: Latest results from PubMed

Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map

Polycystic ovary syndrome (PCOS) is a common, heterogeneous condition that is tightly linked to obesity, visceral adiposity and insulin resistance. Lifestyle intervention and off-label use of metformin provide only modest and unsustained weight loss, insufficient to reverse obesity-driven pathophysiology in most women with PCOS and obesity. Incretin-based anti-obesity medications, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic...

Published on: Sat, 09 May 2026 06:00:00 -0400

Authors: Mojca Jensterle, Andrej Janez,

Approach to the diagnosis and treatment of polycystic ovarian syndrome in adolescent patients

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. Its diagnosis during adolescence is particularly challenging, as physiological pubertal changes overlap with key features of PCOS; nevertheless, this developmental stage often represents the earliest window for clinical manifestation. Accordingly, a definitive diagnosis should be established only in the presence of clear and persistent evidence of both hyperandrogenism and...

Published on: Sat, 09 May 2026 06:00:00 -0400

Authors: Iza Franklin Roza Machado, Flavia Rezende Tinano, Ana Claudia Latronico, Larissa Garcia Gomes,

The effects of omentin on estradiol and progesterone release in human granulosa cell culture

Adipokines serve as a link between energy metabolism and reproduction, helping to explain infertility related to polycystic ovary syndrome (PCOS). Granulosa cells are known to produce adipokines such as omentin; however, research on the potential effects of omentin on hormone levels in PCOS patients is lacking. Thus, the aim of our study was to evaluate the effect of different concentrations of omentin, FSH, and FSH + omentin on estradiol and progesterone secretion from human granulosa cells of...

Published on: Fri, 08 May 2026 06:00:00 -0400

Authors: Pınar Tarıkahya, Burcu Baba, Leyla Özer, Tolga Ecemiş, Çağla Zübeyde Köprü,

Alnustone ameliorates obesity and polycystic ovary syndrome by remodeling adipose metabolism via AMPK signaling

Polycystic ovary syndrome (PCOS) is a prevalent reproductive and metabolic disorder frequently accompanied by obesity, creating a dual burden of infertility and metabolic disease for women, yet therapeutic options addressing both pathologies remain limited. Here, using high-fat diet-induced obese and dehydroepiandrosterone-induced PCOS mouse models, we demonstrate that alnustone, a naturally derived compound, exerts coordinated benefits on both metabolic and reproductive dysfunctions in females....

Published on: Fri, 08 May 2026 06:00:00 -0400

Authors: Yiming Qin, Shourui Hu, Yanqi Xu, Zongxuan Lin, Xiaofan Liang, Yue Liu, Yuxuan Li, Chunxuan Geng, Xiangyan Chen, Xizi Feng, Zi-Jiang Chen, Han Zhao, Yuqing Zhang,

Autoimmune diseases in patients with different PCOS phenotypes

CONCLUSIONS: Organ-specific and systemic autoimmune disorders affect 22.6% of the PCOS women. The investigation of autoimmune markers in diabetic women with PCOS might be essential for the precise diagnosis. Further studies on associations between PCOS, skin and systemic inflammatory disorders might be of clinical importance.

Published on: Fri, 08 May 2026 06:00:00 -0400

Authors: Ralitsa Robeva, Georgi Kirilov, Krassimir Kalinov, Atanaska Elenkova,

Role of Functional Foods and Nutraceutical Compounds in Alleviating Polycystic Ovary Syndrome: A Narrative Review

Polycystic ovary syndrome (PCOS) represents one of the most common endocrine disorders among women of reproductive age. It is often associated with hormonal imbalance, metabolic disturbances, and reproductive complications, which together contribute to an elevated risk of long-term cardiometabolic disorders. Limitations and side effects of conventional pharmacotherapies have prompted growing interest in nutrition-based adjunct strategies targeting core PCOS pathophysiology. To narratively...

Published on: Fri, 08 May 2026 06:00:00 -0400

Authors: Pooja Singnale, Debasis Sasmal, Surya Goud S Chukkala, Monica Chilumula, Raghavendra Pandurangi, Soibam Peter Singh, Mahesh Kumar Mummadi, Ramesh Gondru,

Integrative Machine Learning Models to Unravel Gut Microbial Dysbiosis and Functional Disruption in Polycystic Ovary Syndrome

CONCLUSION: The gut microbiome in PCOS is characterized by a pro-inflammatory community structure and disrupted metabolic pathways. These findings demonstrate the diagnostic potential of microbiome-based models and underscore the gut microbiome as a promising target for therapeutic interventions in the management of PCOS.

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Geetika Devi Kaliappa, Hema Palanisamy, Subramanian Vidyalakshmi,

Rationally design and create an activatable probe to monitor peroxynitrite in the mice model of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) stands as a formidable global public health challenge, necessitating advanced diagnostic modalities. Herein, we report the development and multifaceted application of HD-ONOO, an innovative hemicyanine-based fluorescent scaffold engineered for the highly selective, real-time monitoring of peroxynitrite (ONOO^(-))-a pivotal reactive oxygen species (ROS) linked to PCOS pathology. Upon site-specific interaction with ONOO^(-), the probe undergoes a structured...

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Xiaoling Ren, Hua Wang, Kai Wang, Liyun Mao, Weibo Zhao, Baohong Ren,

Quercetin-3-Glucoside from Ocimum basilicum ameliorates polycystic ovary syndrome by targeting the IL-6/JAK-STAT3 signaling axis

Chronic inflammation is a key contributor to the pathophysiology of polycystic ovary syndrome (PCOS), disrupting hormonal signaling and ovarian function. This study investigated the therapeutic potential of Quercetin-3-Glucoside (Q3G), a bioactive flavonoid from Ocimum basilicum (OB), against PCOS-associated inflammation. An integrated approach of network pharmacology and molecular docking predicted Q3G interaction with key inflammatory targets IL6, STAT3, and BCL2, predominantly through the...

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Hina Majid Khan, Imran Tarique, Mohadsa Zainab, Syeda Maryam Hussain, Nimra Rehman,

Androgenetic Alopecia in Polycystic Ovary Syndrome: A Cutaneous Marker of Systemic Metabo-inflammatory and Endocrine Dysfunction: A Narrative Review

Polycystic Ovary Syndrome (PCOS) is a multifaceted endocrine-metabolic disorder in which androgenetic alopecia (AGA) serves as a prominent clinical marker of profound systemic dysregulation, extending beyond simple hyperandrogenism. This condition imposes a significant psychosocial burden on affected women, yet its complete pathophysiology remains incompletely understood, leading to therapeutic plateaus. This review advances the central hypothesis that alopecia in PCOS results from a synergistic...

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Farzaneh Motafeghi, Marzieh Saei Ghare Naz, Fahimeh Ramezani Tehrani, Samira Behboudi Gandevani,

AutoPCOS: a stepwise multimodal intelligent framework for polycystic ovary syndrome risk stratification and diagnostic support

INTRODUCTION: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder among women of reproductive age, typically diagnosed through a combination of clinical evaluation, laboratory testing, and ultrasonography. However, this multimodal diagnostic pathway is often time-consuming, costly, and dependent on resource availability, thereby limiting its accessibility in real-world clinical settings.

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Jianping Hou, Yirui Duan, Wanli Zhao, Qianpeng Sun, Jiayin Wang,

Lipid metabolism abnormalities induced by elevated PCSK9 in PCOS mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3beta

Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder among women of childbearing age, significantly impacting their fertility needs. Granulosa cell apoptosis in the ovaries is one of the primary factors affecting follicular growth and development as well as oocyte maturation in PCOS, yet its pathological mechanisms remain unclear. Our previous research revealed that elevated PCSK9 expression in PCOS mice affects ovarian function. This study further investigated the...

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Wending Teng, Dan Zhao, Kaiyun Luo, Pan Zhang, Li Nie, Yicheng Wang,

Artificial intelligence in ovarian pathophysiology and management: a systematic review and meta-analysis

CONCLUSION: AI holds significant promise for personalizing and improving care for ovarian conditions. Translation from research to routine clinical practice requires rigorous prospective multicenter validation, standardized methodological and reporting frameworks, seamless clinical workflow integration, and robust ethical and regulatory governance to ensure responsible, equitable implementation.

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Hang Yu, Lifan Peng,

A New Diagnostic Strategy for Polycystic Ovary Syndrome Combining Japanese and International Diagnostic Criteria Using Anti-Müllerian Hormone

CONCLUSION: Applying elevated serum AMH (level 2) based on the Rotterdam/IEBG 2023 criteria improved the diagnostic rate of PCOS, particularly in non-obese/overweight patients and relatively older women with milder PCOS phenotypes. This new approach is practical, complementary, and can help overcome limitations of the diagnosis of PCOS and thus expand diagnostic opportunities.

Published on: Thu, 07 May 2026 06:00:00 -0400

Authors: Hiroki Noguchi, Takeshi Iwasa, Akira Iwase, Haruhiko Kanasaki, Fuminori Kimura, Koji Kugu, Kazuki Saito, Tsuyoshi Baba, Tetsuaki Hara, Toshiya Matsuzaki,

Exploring the therapeutic potential of Lupeol isolated from Ochrosia elliptica Labill. leaves in polycystic ovarian syndrome

This study evaluated the therapeutic potential of lupeol (LUP), a naturally occurring pentacyclic triterpenoid isolated from Ochrosia elliptica (Labill)., in a rat model of letrozole-induced polycystic ovary syndrome (PCOS). Thirty-five adults female Wistar rats were randomly allocated into five groups: normal control, PCOS model, clomiphene citrate-treated (1 mg/kg), and two LUP-treated groups (10 and 20 mg/kg). Following PCOS induction, treatments were administered orally for 28 consecutive...

Published on: Wed, 06 May 2026 06:00:00 -0400

Authors: Essam Abdel-Sattar, Marwa A Ibrahim, Fady Sayed Youssef, Marwa S Khattab, Riham A El-Shiekh, Rehab A Ghandour, Shimaa R Emam, Heba Hozyen, Marwa Zakaria, Samar M Mouneir,